Unlocking Bevacizumab's Potential: rCBV max as a Predictive Biomarker for Enhanced Survival in Glioblastoma IDH-Wildtype Patients.

María Del Mar Álvarez-TorresCarmen Balaña Quintero Elies Fuster-Garcia Josep Puig Juan Miguel García-Gómez

Published in: Cancers (2023)

We propose rCBVmax as a potential biomarker to select patients who can benefit more from BVZ after tumor progression. In addition, we propose a threshold of 7.5 to stratify patients into moderate- and high-vascular groups to select the optimal second-line treatment.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
prognostic factors
patient reported outcomes
poor prognosis
risk assessment
low grade
long non coding rna
human health